13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03161028 (ClinicalTrials.gov) | July 1, 2018 | 18/5/2017 | Lipoic Acid for Progressive Multiple Sclerosis (MS) | Lipoic Acid for the Treatment of Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Lipoic acid;Drug: Placebo | VA Office of Research and Development | NULL | Recruiting | 18 Years | 70 Years | All | 118 | Phase 2 | United States;Canada |
2 | NCT03493841 (ClinicalTrials.gov) | June 8, 2018 | 21/3/2018 | Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis | Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial | Multiple Sclerosis;Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis | Drug: Alpha Lipoic Acid | Rebecca Spain | NULL | Completed | 18 Years | N/A | All | 20 | Phase 1 | United States |
3 | NCT02133664 (ClinicalTrials.gov) | June 2014 | 6/5/2014 | Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis | Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis | Multiple Sclerosis;Cognition | Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo | Oregon Health and Science University | National Multiple Sclerosis Society | Completed | 18 Years | 65 Years | All | 54 | Phase 1;Phase 2 | United States |
4 | NCT01381354 (ClinicalTrials.gov) | October 2010 | 26/5/2011 | Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) | Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) | Multiple Sclerosis | Other: Progressive exercise;Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;Other: Modified paleolithic diet;Dietary Supplement: Omega 3 fatty acids;Dietary Supplement: Full Spectrum vitamin;Dietary Supplement: Essential - hydroxytyrosol;Dietary Supplement: Maltodextrin fiber supplement;Dietary Supplement: Mineral boost (magnesium);Dietary Supplement: Niacinamide;Dietary Supplement: Methyl B12;Dietary Supplement: Taurine;Dietary Supplement: creatine;Dietary Supplement: thiamine;Dietary Supplement: riboflavin;Dietary Supplement: N acetylcysteine;Dietary Supplement: alpha lipoic acid;Dietary Supplement: L acetyl carnitine;Dietary Supplement: methyl folate;Dietary Supplement: coenzyme Q;Behavioral: meditation;Behavioral: self massage;Behavioral: learning;Dietary Supplement: Coconut oil | University of Iowa | Direct MS Canada;DJO Incorporated;Pinnaclife Inc.;TZ Press, LLC | Completed | 18 Years | 65 Years | All | 38 | Phase 1 | United States |
5 | NCT01188811 (ClinicalTrials.gov) | October 2010 | 25/8/2010 | Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) | Lipoic Acid for Neuroprotection in Secondary Progressive MS | Multiple Sclerosis, Chronic Progressive | Drug: lipoic acid;Drug: Placebo | VA Office of Research and Development | Oregon Health and Science University | Completed | 40 Years | 70 Years | All | 54 | Phase 2;Phase 3 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT00997438 (ClinicalTrials.gov) | August 2010 | 16/10/2009 | Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis | Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: Lipoic Acid | Portland VA Medical Center | Oregon Health and Science University | Completed | 18 Years | N/A | All | 69 | Phase 1 | United States |
7 | NCT00676156 (ClinicalTrials.gov) | December 2005 | 7/5/2008 | A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis | A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis | Multiple Sclerosis | Drug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acid | Oregon Health and Science University | National Center for Complementary and Integrative Health (NCCIH) | Completed | 18 Years | 80 Years | Both | 40 | Phase 1 | United States |
8 | NCT00010842 (ClinicalTrials.gov) | September 1999 | 2/2/2001 | Natural Antioxidants in the Treatment of Multiple Sclerosis | Natural Antioxidants in the Treatment of Multiple Sclerosis | Multiple Sclerosis | Drug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acids | National Center for Complementary and Integrative Health (NCCIH) | NULL | Completed | N/A | N/A | Both | Phase 1;Phase 2 | United States |